
ClinicalTrials.gov shows completed Phase 3 trial NCT02385188 tested topical 5% imiquimod for vulvar Paget's. Lens.org patents report successful 'Topical Calcipotriol Plus Imiquimod Immunotherapy' (2023). Imiquimod activates TLR7/8 inducing local immune response while calcipotriol modulates vitamin D receptor affecting cell differentiation.
IPFS: QmUFg94Zr6sNHjJJpsthUb16HRXAso9exCBST31JLv2624. TX: 0x0c0b2c8ace9311855ed920e5b2a048824ca4e7828c826a71daa4a0bf66ac96ee. CC0.
combination, drug repurposing, MedicOath, Extramammary Paget disease
combination, drug repurposing, MedicOath, Extramammary Paget disease
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
